NCM
TRDA icon

Nantahala Capital Management’s Entrada Therapeutics TRDA Stock Holding History

Nantahala Capital Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21M Buy
300,575
+141,243
+89% +$1.35M 0.07% 135
2026
Q1 		$2.01M Buy
+159,332
New +$1.83M 0.07% 135

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Nantahala Capital Management's TRDA Position: Q2 2026 in Review

Nantahala Capital Management increased its Entrada Therapeutics (TRDA) stake by 89% in Q2 2026, buying an estimated $1.35M and bringing the position to 300,575 shares worth $2.21M. The position accounts for 0.07% of the portfolio, ranked #135.

Nantahala Capital Management first reported a position in TRDA in Q1 2026 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Nantahala Capital Management held 300,575 shares of Entrada Therapeutics worth $2.21M as of Q2 2026.
  • Nantahala Capital Management bought 141,243 Entrada Therapeutics shares in Q2 2026, an estimated $1.35M.
  • Entrada Therapeutics made up 0.07% of Nantahala Capital Management's portfolio in Q2 2026, its #135 holding.
  • Nantahala Capital Management first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.